<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="33794d74-d742-82b5-e063-6294a90a6f32"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>These highlights do not include all the information needed to use ZERVIATE 
 <sup>®</sup>safely and effectively. See full prescribing information for ZERVIATE 
 <sup>®</sup>.
 <br/>
ZERVIATE 
 <sup>®</sup>(cetirizine ophthalmic solution) 0.24%, for topical ophthalmic use
 <br/>
Initial U.S. Approval: 1995
</title>
   <effectiveTime value="20250423"/>
   <setId root="6fc5ef4e-4aea-4c34-8d51-0c07ab9aad59"/>
   <versionNumber value="2"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="118526951"/>
            <name>Harrow Eye, LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id root="1.3.6.1.4.1.519.1" extension="274234566"/>
                        <name>Excelvision</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C43360" displayName="manufacture" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82667-015" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C25391" displayName="analysis" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82667-015" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" displayName="label" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82667-015" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" displayName="pack" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="82667-015" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="337a819c-5724-4ec1-e063-6294a90a21a9"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250423"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="82667-015" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>ZERVIATE</name>
                        <formCode code="C60927" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="FOR SOLUTION"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>cetirizine</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="F5UM2KM3W7" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>BENZALKONIUM CHLORIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="PDC6A3C0OX" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GLYCERIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="RN3152OP35" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (4000 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="B697894SGQ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 400</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="GR686LBA74" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM PHOSPHATE, DIBASIC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="QTT17582CB" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROCHLORIC ACID</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="2.4"/>
                              <denominator unit="mL" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="YO7261ME24" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CETIRIZINE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="YO7261ME24" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CETIRIZINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="2.5" unit="mL"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43216" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VIAL, SINGLE-USE"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="30" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code/>
                                    <formCode code="C43200" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="POUCH"/>
                                    <asContent>
                                       <quantity>
                                          <numerator value="1" unit="1"/>
                                          <denominator value="1"/>
                                       </quantity>
                                       <containerPackagedProduct>
                                          <code code="82667-015-24" codeSystem="2.16.840.1.113883.6.69"/>
                                          <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                       </containerPackagedProduct>
                                       <subjectOf>
                                          <marketingAct>
                                             <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                             <statusCode code="active"/>
                                             <effectiveTime>
                                                <low value="20250430"/>
                                             </effectiveTime>
                                          </marketingAct>
                                       </subjectOf>
                                    </asContent>
                                 </containerPackagedProduct>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102835" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 2: Prefilled Drug Delivery Device/System (syringe, patch, etc.)" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA208694" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250430"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38287" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="OPHTHALMIC"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="s1">
               <id root="33794d74-d743-82b5-e063-6294a90a6f32"/>
               <code code="43683-2" codeSystem="2.16.840.1.113883.6.1" displayName="RECENT MAJOR CHANGES SECTION"/>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <table width="100%" styleCode="Noautorules">
                           <col width="81.850%" align="left"/>
                           <col width="18.150%" align="left"/>
                           <tbody>
                              <tr>
                                 <td align="left" valign="top">Dosage and Administration (
    
       <linkHtml href="#s3">2</linkHtml>)
   
      </td>
                                 <td align="right" valign="top">2/2020</td>
                              </tr>
                              <tr>
                                 <td align="left" valign="top">Warnings and Precautions (
    
       <linkHtml href="#s7">5.1</linkHtml>)
   
      </td>
                                 <td align="right" valign="top">2/2020</td>
                              </tr>
                           </tbody>
                        </table>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s2">
               <id root="33794d74-d744-82b5-e063-6294a90a6f32"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>ZERVIATE
 
  <sup>®</sup>(cetirizine ophthalmic solution) 0.24% is indicated for the treatment of ocular itching associated with allergic conjunctivitis.

 </paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>ZERVIATE
 
    <sup>®</sup>(cetirizine ophthalmic solution) 0.24% is a histamine-1 (H1) receptor antagonist indicated for treatment of ocular itching associated with allergic conjunctivitis. (
 
    <linkHtml href="#s2">1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s3">
               <id root="33795a9c-e795-5671-e063-6394a90a5b88"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dosage of ZERVIATE
  <sup>® </sup>is to instill one drop in each affected eye twice daily (approximately 8 hours apart).
 </paragraph>
                  <paragraph>
                     <content styleCode="xmChange">The single-use containers are to be used immediately after opening and can be used to dose both eyes. Discard the single-use container and any remaining contents after administration. The single-use containers should be stored in the original foil pouch until ready to use.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The recommended dose is one drop in each affected eye twice daily. ( 
    <linkHtml href="#s3">2</linkHtml>)
   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s4">
               <id root="33794d74-d746-82b5-e063-6294a90a6f32"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Cetirizine ophthalmic solution, 0.24% is a sterile, buffered, clear, colorless aqueous solution containing cetirizine 0.24% (equivalent to cetirizine hydrochloride 0.29%).</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Ophthalmic solution: 2.4 mg cetirizine in 1 mL sterile solution (0.24%). (
 
    <linkHtml href="#s4">3</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s5">
               <id root="33794d74-d747-82b5-e063-6294a90a6f32"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>None.</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>None. (
 
    <linkHtml href="#s5">4</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s6">
               <id root="33794d74-d748-82b5-e063-6294a90a6f32"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Contamination of Tip and Solution. To prevent contaminating the dropper tip and solution, advise patients not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container. (
 
    <linkHtml href="#s7">5.1</linkHtml>)

   </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="s7">
                     <id root="33794d74-d749-82b5-e063-6294a90a6f32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Contamination of Tip and Solution</title>
                     <text>
                        <paragraph>
                           <content styleCode="xmChange">As with any eye drop, care should be taken not to touch the eyelids or surrounding areas with the dropper tip of the bottle or tip of the single-use container in order to avoid injury to the eye and to prevent contaminating the tip and solution. Keep the multi-dose bottle closed when not in use. Discard the single-use container after using in each eye.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="s8">
                     <id root="33794d74-d74a-82b5-e063-6294a90a6f32"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Contact Lens Wear</title>
                     <text>
                        <paragraph>Patients should be advised not to wear a contact lens if their eye is red.</paragraph>
                        <paragraph>ZERVIATE
 
  <sup>®</sup>should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of ZERVIATE
 
  <sup>®</sup>. The preservative in ZERVIATE
 
  <sup>®</sup>, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE
 
  <sup>®</sup>.

 </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s9">
               <id root="33794d74-d74b-82b5-e063-6294a90a6f32"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trial of a drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates in practice.</paragraph>
                  <paragraph>In seven clinical trials, patients with allergic conjunctivitis or those at a risk of developing allergic conjunctivitis received one drop of either cetirizine (N=511) or vehicle (N=329) in one or both eyes. The most commonly reported adverse reactions occurred in approximately 1–7% of patients treated with either ZERVIATE
 
  <sup>®</sup>or vehicle. These reactions were ocular hyperemia, instillation site pain, and visual acuity reduced.

 </paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions (1–7%) were ocular hyperemia, instillation site pain, and visual acuity reduced. (
 
    <linkHtml href="#s9">6</linkHtml>)

   </paragraph>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Harrow at 1-833-4HARROW(427769) or FDA at 1-800-FDA-1088 or</content>
                           <content styleCode="bold">
                              <content styleCode="italics">www.fda.gov/medwatch.</content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="s10">
               <id root="33794d74-d74c-82b5-e063-6294a90a6f32"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="s11">
                     <id root="33794d74-d74d-82b5-e063-6294a90a6f32"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section ID="s12">
                           <id root="33794d74-d74e-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Risk Summary</content>
                              </paragraph>
                              <paragraph>There were no adequate or well-controlled studies with ZERVIATE
 
  <sup>®</sup>in pregnant women.

 </paragraph>
                              <paragraph>Cetirizine should be used in pregnancy only if the potential benefit justifies the potential risk to the fetus.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section ID="e13">
                           <id root="33794d74-d74f-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Data</content>
                              </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                           <component>
                              <section ID="s13">
                                 <id root="33794d74-d750-82b5-e063-6294a90a6f32"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <text>
                                    <paragraph>
                                       <content styleCode="underline">Animal Data</content>
                                    </paragraph>
                                    <paragraph>Cetirizine was not teratogenic in mice, rats, or rabbits at oral doses up to 96, 225, and 135 mg/kg, respectively (approximately 1300, 4930, and 7400 times the maximum recommended human ophthalmic dose (MRHOD), on a mg/m
 
  <sup>2</sup>basis).

 </paragraph>
                                 </text>
                                 <effectiveTime value="20241130"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s14">
                     <id root="33794d74-d751-82b5-e063-6294a90a6f32"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section ID="s15">
                           <id root="33794d74-d752-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Risk Summary</content>
                              </paragraph>
                              <paragraph>Cetirizine has been reported to be excreted in human breast milk following oral administration. Multiple doses of oral dose cetirizine (10 mg tablets once daily for 10 days) resulted in systemic levels (Mean C
 
  <sub>max</sub>= 311 ng/mL) that were 100 times higher than the observed human exposure (Mean C
 
  <sub>max</sub>= 3.1 ng/ mL) following twice daily administration of cetirizine ophthalmic solution 0.24% to both eyes for one week
 
  <content styleCode="italics">[see Clinical Pharmacology (
  
   <linkHtml href="#s21">12.3</linkHtml>)]
 
  </content>. Comparable bioavailability has been found between the tablet and syrup dosage forms. However, it is not known whether the systemic absorption resulting from topical ocular administration of ZERVIATE
 
  <sup>®</sup>could produce detectable quantities in human breast milk.

 </paragraph>
                              <paragraph>There is no adequate information regarding the effects of cetirizine on breastfed infants, or the effects on milk production to inform risk of ZERVIATE
 
  <sup>®</sup>to an infant during lactation. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for ZERVIATE
 
  <sup>®</sup>and any potential adverse effects on the breastfed child from ZERVIATE
 
  <sup>®</sup>.

 </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="s16">
                     <id root="33794d74-d753-82b5-e063-6294a90a6f32"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of ZERVIATE
 
  <sup>®</sup>(cetirizine ophthalmic solution) 0.24% has been established in pediatric patients two years of age and older. Use of ZERVIATE
 
  <sup>®</sup>in these pediatric patients is supported by evidence from adequate and well-controlled studies of ZERVIATE
 
  <sup>®</sup>in pediatric and adult patients.

 </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="s17">
                     <id root="33794d74-d754-82b5-e063-6294a90a6f32"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>No overall differences in safety or effectiveness have been observed between elderly and younger patients.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s18">
               <id root="33794d74-d755-82b5-e063-6294a90a6f32"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>ZERVIATE
 
  <sup>®</sup>is a sterile ophthalmic solution containing cetirizine, which is a histamine-1 (H1) receptor antagonist, for topical administration to the eyes. Cetirizine hydrochloride is a white, crystalline, water-soluble powder with a molecular weight of 461.8 and a molecular formula of C
 
  <sub>21</sub>H
 
  <sub>25</sub>ClN
 
  <sub>2</sub>O
 
  <sub>3</sub>•2HCl. The chemical structure is presented below:

 </paragraph>
                  <renderMultiMedia ID="f01" referencedObject="mm01"/>
                  <paragraph>Chemical Name:</paragraph>
                  <paragraph>(
 
  <content styleCode="italics">RS</content>)-2-[2-[4-[(4-Chlorophenyl) phenylmethyl] piperazin-1-yl] ethoxy] acetic acid, dihydrochloride

 </paragraph>
                  <paragraph>Each mL of ZERVIATE
 
  <sup>®</sup>contains an active ingredient [cetirizine 2.40 mg (equivalent to 2.85 mg of cetirizine hydrochloride)] and the following inactive ingredients: benzalkonium chloride 0.010% (preservative); glycerin; sodium phosphate, dibasic; edetate disodium; polyethylene glycol 400; polysorbate 80; hypromellose; hydrochloric acid/sodiumhydroxide (to adjust pH); and water for injection. ZERVIATE
 
  <sup>®</sup>solution has a pH of approximately 7.0 and osmolality of approximately 300 mOsm/kg.

 </paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <observationMedia ID="mm01">
                     <text>Chemical Structure
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zer00-0000-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="s19">
               <id root="33794d74-d756-82b5-e063-6294a90a6f32"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="s20">
                     <id root="33794d74-d757-82b5-e063-6294a90a6f32"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>ZERVIATE
 
  <sup>®</sup>, an antihistamine, is a histamine-1 (H1) receptor antagonist. Its effects are mediated via selective inhibition of H1 histamine receptors. The antihistaminic activity of cetirizine has been documented in a variety of animal and human models.
 
  <content styleCode="italics">In vivo</content>and
 
  <content styleCode="italics">ex vivo</content>animal models have shown negligible anticholinergic and antiserotonergic activity.
 
  <content styleCode="italics">In vitro</content>receptor binding studies have shown no measurable affinity for other than H1 receptors.

 </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
               <component>
                  <section ID="s21">
                     <id root="33794d74-d758-82b5-e063-6294a90a6f32"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>In healthy subjects, bilateral topical ocular dosing of one drop of ZERVIATE
 
  <sup>®</sup>resulted in a mean cetirizine plasma C
 
  <sub>max</sub>of 1.7 ng/mL following a single dose and 3.1 ng/mL after twice-daily dosing for one week. The observed mean terminal half-life of cetirizine was 8.6 hours following a single dose and 8.2 hours after twice-daily dosing of ZERVIATE
 
  <sup>®</sup>for one week.

 </paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s22">
               <id root="33794d74-d759-82b5-e063-6294a90a6f32"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="s23">
                     <id root="33794d74-d75a-82b5-e063-6294a90a6f32"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <effectiveTime value="20241130"/>
                     <component>
                        <section ID="s24">
                           <id root="33794d74-d75b-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Carcinogenicity</content>
                              </paragraph>
                              <paragraph>In a 2-year carcinogenicity study in rats, orally administered cetirizine was not carcinogenic at dietary doses up to 20 mg/ kg (approximately 550 times the MRHOD, on a mg/m
 
  <sup>2</sup>basis). In a 2-year carcinogenicity study in mice, cetirizine caused an increased incidence of benign liver tumors in males at a dietary dose of 16 mg/kg (approximately 220 times the MRHOD, on a mg/m
 
  <sup>2</sup>basis). No increase in the incidence of liver tumors was observed in mice at a dietary dose of 4 mg/kg (approximately 55 times the MRHOD, on a mg/m
 
  <sup>2</sup>basis). The clinical significance of these findings during long-term use of cetirizine is not known.

 </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s25">
                           <id root="33794d74-d75c-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Mutagenesis</content>
                              </paragraph>
                              <paragraph>Cetirizine was not mutagenic in the Ames test or in an
 
  <content styleCode="italics">in vivo</content>micronucleus test in rats.

 </paragraph>
                              <paragraph>Cetirizine was not clastogenic in the human lymphocyte assay or the mouse lymphoma assay.</paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                     <component>
                        <section ID="s26">
                           <id root="33794d74-d75d-82b5-e063-6294a90a6f32"/>
                           <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                           <text>
                              <paragraph>
                                 <content styleCode="italics">Impairment of Fertility</content>
                              </paragraph>
                              <paragraph>In a fertility and general reproductive performance study in mice, cetirizine did not impair fertility at an oral dose of 64 mg/kg (approximately 875 times the MRHOD on a mg/m
 
  <sup>2</sup>basis).

 </paragraph>
                           </text>
                           <effectiveTime value="20241130"/>
                        </section>
                     </component>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s27">
               <id root="33794d74-d75e-82b5-e063-6294a90a6f32"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>The efficacy of ZERVIATE
 
  <sup>®</sup>(cetirizine ophthalmic solution) 0.24% was established in three randomized, double-masked, placebocontrolled, conjunctival allergen challenge (CAC) clinical trials in patients with a history of allergic conjunctivitis. Onset and duration of action were evaluated in two of these trials in which patients were randomized to receive ZERVIATE
 
  <sup>®</sup>or vehicle ophthalmic solutions. Patients were evaluated with an ocular itching severity score ranging from 0 (no itching) to 4 (incapacitating itch) at several time points after CAC administration.
 
  <linkHtml href="#t1">Table 1</linkHtml>displays data from the mean ocular itching severity scores after ocular administration of an antigen using the CAC model. A one unit difference compared to vehicle is considered a clinically meaningful change in the ocular itching severity score.

 </paragraph>
                  <paragraph>Patients treated with ZERVIATE
 
  <sup>®</sup>demonstrated statistically and clinically significantly less ocular itching compared to vehicle at 15 minutes and 8 hours after treatment.

 </paragraph>
                  <table ID="t1" width="100%" styleCode="Noautorules">
                     <caption>Table 1 Itching Scores in the ITT Population by Treatment Group and Treatment Difference</caption>
                     <col width="13.308%" align="left"/>
                     <col width="11.820%" align="left"/>
                     <col width="9.853%" align="left"/>
                     <col width="11.820%" align="left"/>
                     <col width="9.853%" align="left"/>
                     <col width="11.820%" align="left"/>
                     <col width="9.853%" align="left"/>
                     <col width="11.820%" align="left"/>
                     <col width="9.853%" align="left"/>
                     <tfoot>
                        <tr>
                           <td colspan="9" align="left" styleCode="Lrule Rrule" valign="top">
                              <paragraph styleCode="footnote">
                                 <sup>1</sup>Treatment difference values shown are the group mean active minus the group mean vehicle at each post-CAC time point.
    
     </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="9" align="left" styleCode="Botrule Lrule Rrule" valign="top">
                              <paragraph styleCode="footnote">* p&lt;0.05</paragraph>
                           </td>
                        </tr>
                     </tfoot>
                     <tbody>
                        <tr>
                           <td align="left" styleCode="Botrule Rrule" valign="top"/>
                           <td colspan="4" align="center" styleCode="Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold">Study 1</content>
                           </td>
                           <td colspan="4" align="center" styleCode="Toprule Botrule Rrule" valign="top">
                              <content styleCode="bold">Study 2</content>
                           </td>
                        </tr>
                        <tr>
                           <td rowspan="2" align="center" styleCode="Botrule Lrule Rrule" valign="middle">
                              <content styleCode="bold">Statistics</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">15 minutes post-treatment</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">8 hours post-treatment</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">15 minutes post-treatment</content>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">8 hours post-treatment</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="top">
                              <content styleCode="bold">ZERVIATE N=50</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Vehicle</content>
                              <br/>
                              <content styleCode="bold">N=50</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">ZERVIATE N=50</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Vehicle</content>
                              <br/>
                              <content styleCode="bold">N=50</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">ZERVIATE N=51</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Vehicle</content>
                              <br/>
                              <content styleCode="bold">N=50</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">ZERVIATE N=51</content>
                           </td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">
                              <content styleCode="bold">Vehicle</content>
                              <br/>
                              <content styleCode="bold">N=50</content>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="9" align="left" styleCode="Botrule Lrule Rrule" valign="top">
                              <content styleCode="bold">3 Minute Post-CAC</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode="Botrule Lrule Rrule" valign="top">Mean</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.00</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.38</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.76</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.69</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.01</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.54</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.94</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.86</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Treatment 
     <br/>  Difference 
     <br/>  (95% CI)
    
     <sup>1</sup>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.38 
     <br/>  (-1.72, -1.05)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.93 
     <br/>  (-1.26, -0.61)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.53 
     <br/>  (-1.92, -1.15)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.92 
     <br/>  (-1.25, -0.58)*
    </td>
                        </tr>
                        <tr>
                           <td colspan="9" align="left" styleCode="Botrule Lrule Rrule" valign="top">
                              <content styleCode="bold">5 Minute Post-CAC</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Mean</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.18</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.43</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.85</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.74</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.17</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.51</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.03</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.94</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Treatment 
     <br/>  Difference 
     <br/>  (95% CI)
    
     <sup>1</sup>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.25 
     <br/>  (-1.58, -0.91)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.89 
     <br/>  (-1.24, -0.54)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.34 
     <br/>  (-1.71, -0.97)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.90 
     <br/>  (-1.23, -0.57)*
    </td>
                        </tr>
                        <tr>
                           <td colspan="9" align="left" styleCode="Botrule Lrule Rrule" valign="top">
                              <content styleCode="bold">7 Minute Post-CAC</content>
                           </td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Mean</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.11</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.11</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.54</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.53</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.15</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.23</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">1.82</td>
                           <td align="center" styleCode="Botrule Rrule" valign="top">2.66</td>
                        </tr>
                        <tr>
                           <td align="left" styleCode="Botrule Lrule Rrule" valign="top">Treatment 
     <br/>  Difference 
     <br/>  (95% CI)
    
     <sup>1</sup>
                           </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.00 
     <br/>  (-1.35, -0.65)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.99 
     <br/>  (-1.40, -0.59)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-1.07 
     <br/>  (-1.46, -0.69)*
    </td>
                           <td colspan="2" align="center" styleCode="Botrule Rrule" valign="middle">-0.84 
     <br/>  (-1.21, -0.48)*
    </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241130"/>
            </section>
         </component>
         <component>
            <section ID="s28">
               <id root="33794d74-d75f-82b5-e063-6294a90a6f32"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>ZERVIATE
 
  <sup>®</sup>is a sterile, buffered, clear, colorless aqueous solution containing cetirizine 0.24% (equivalent to cetirizine hydrochloride 0.29%) supplied in a white low-density polyethylene multi-dose ophthalmic bottle with a low-density polyethylene dropper tip and a white polypropylene cap. ZERVIATE
 
  <sup>®</sup>is supplied in a 7.5 mL bottle that contains 5 mL and a 10 mL bottle that contains 7.5 mL cetirizine ophthalmic solution, 2.40 mg [equivalent to 2.85 mg cetirizine hydrochloride in one mL solution]. ZERVIATE
 
  <sup>®</sup>is also supplied in 5 low-density polyethylene 0.2 mL single-use containers within a foil pouch.

 </paragraph>
                  <paragraph>Carton of 30 single-use containers NDC 82667-015-24</paragraph>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <section ID="s29">
                     <id root="33794d74-d760-82b5-e063-6294a90a6f32"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Storage:</content>Store at 15°C to 25°C (59°F to 77°F).

 </paragraph>
                        <paragraph>Single-use containers should be stored in the original foil pouch.</paragraph>
                     </text>
                     <effectiveTime value="20241130"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="s30">
               <id root="33794d74-d761-82b5-e063-6294a90a6f32"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <list listType="unordered" styleCode="Disc">
                     <item>Risk of Contamination: Advise patients not to touch dropper tip to eyelids or surrounding areas, as this may contaminate the dropper tip and ophthalmic solution. Advise patients to keep the bottle closed when not in use. Advise patients to discard single-use containers after each use.</item>
                     <item>Concomitant Use of Contact Lenses: Advise patients not to wear contact lenses if their eyes are red. Advise patients that ZERVIATE
  
   <sup>®</sup>should not be used to treat contact lens-related irritation. Advise patients to remove contact lenses prior to instillation of ZERVIATE
  
   <sup>®</sup>. The preserative in ZERVIATE
  
   <sup>®</sup>solution, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted 10 minutes following administration of ZERVIATE
  
   <sup>®</sup>.
 
  </item>
                     <item>Administration: Advise patients that the solution from one single-use container is to be used immediately after opening. Advise patients that the single-use container can be used to dose both eyes. Discard the single-use container and remaining contents immediately after administration.</item>
                     <item>Storage of Single-use Containers: Instruct patients to store single-use containers in the original foil pouch until ready to use.</item>
                  </list>
                  <paragraph>Rev 11/2024</paragraph>
                  <paragraph>
                     <content styleCode="bold">Manufactured for: 
   <br/>
                     </content>Harrow Eye, LLC
 
  <sup>TM</sup>
                     <br/>  Nashville, TN USA

 </paragraph>
                  <paragraph>U.S. Patents: 8,829,005; 9,254,286; 9,750,684; 9,993,471</paragraph>
               </text>
               <effectiveTime value="20241130"/>
            </section>
         </component>
         <component>
            <section ID="s31">
               <id root="33794d74-d762-82b5-e063-6294a90a6f32"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>Principal Display Panel – 2.5 mL Carton Label</title>
               <text>
                  <paragraph>NDC 82667-015-24</paragraph>
                  <paragraph>
                     <content styleCode="bold">ZERVIATE®</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">(cetirizine ophthalmic 
   <br/>  solution) 0.24%
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">30 single use containers</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">6 pouches x 5 single-use containers 
   <br/>  (0.2 mL each)
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR TOPICAL 
   <br/>  OPHTHALMIC USE
  </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only       HARROW®       </content>Sterile

 </paragraph>
                  <renderMultiMedia ID="f02" referencedObject="mm02"/>
               </text>
               <effectiveTime value="20241130"/>
               <component>
                  <observationMedia ID="mm02">
                     <text>Figure
</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="zer00-0000-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>